Alligator Bioscience sells CD40 agonist antibody to Biossil
Alligator Bioscience has signed an agreement to sell all rights and assets related to the CD40 agonist antibody mitazalimab to Biossil. Alligator will receive $750,000 upfront… Read More
Alligator Bioscience has signed an agreement to sell all rights and assets related to the CD40 agonist antibody mitazalimab to Biossil. Alligator will receive $750,000 upfront… Read More
Strand Therapeutics has dosed the first patients in its ASCENT-1 Phase I clinical trial of STX-003, an intravenously delivered self-replicating mRNA therapy designed to selectively express IL-12 within tumours while restricting expression in healthy tissue. This is the first clinical evaluation of Strand’s SignalLock genetic circuitry, designed… Read More
In this contribution to the Fall 2026 issue of DDW, Thomas Edwards, Partnering Lead for C-Further, examines why childhood cancer treatments lag behind adult treatments and what needs to change. Childhood cancer is one of the most underserved areas in oncology Cancer remains the leading… Read More
Biotechnology company TILT Biotherapeutics has presented encouraging results for its TILT-123 therapy at the European Society for Medical Oncology (ESMO) Congress 2026. The company reported on the Phase Ib portion of its PROTA study, which is evaluating TILT-123 (igrelimogene litadenorepvec) in combination with MSD’s anti-PD-1 therapy Keytruda… Read More
Microbiotica has presented clinical data with encouraging efficacy from its Phase Ib MELODY-1 trial of MB097, a precision microbiome therapeutic for patients with advanced melanoma. The data were presented in a poster at the European Society for Medical Oncology (ESMO) Congress 2026. The MELODY-1 trial… Read More
A major new research study has identified potential new ways to treat the most common type of bowel cancer. The study, conducted by an international research team led by The Institute of Cancer Research, London and RCSI University of Medicine and Health Sciences, provides a roadmap for… Read More
The Menarini Group and Stemline Therapeutics, a wholly-owned subsidiary of the Menarini Group, have announced an exclusive worldwide license and collaboration agreement with Georgiamune for GIM-621. GIM-621 is a preclinical-stage first-in-class oral small molecule immunotherapy with potential application across multiple solid tumours. It is one… Read More
NEC Bio has presented results from the Phase I/II TNBC clinical trial of its orally administered individualised neoantigen therapy, NECVAX-NEO1, used in combination with checkpoint inhibitors (CPIs) and chemotherapy for patients with triple-negative breast cancer (TNBC). The findings were presented in an e-poster at the ESMO Congress… Read More
The US Food and Drug Administration (FDA) has granted accelerated approval for a new use of the immunotherapy Jemperli (dostarlimab-gxly). The approval is for Jemperli used alone in adults with previously untreated stage II or stage III locally advanced rectal cancer. Patients with locally advanced… Read More
BioNTech has announced the first topline results from the AHEAD-MERIT Phase II/III clinical trial for its investigational mRNA cancer immunotherapy BNT113 (tenumomeran/raplemomeran or tenu-ra). The clinical trial is evaluating BNT113 in combination with pembrolizumab compared to pembrolizumab monotherapy as a first-line treatment for patients with unresectable recurrent… Read More
Populate, a management platform owned by mixed-use developer Socius, has appointed Dr Angela Kukula as Director of Science and Innovation. Dr Kukula was previously Chief Executive of MedCity and Director of Life Sciences at London & Partners, where she championed London’s life sciences sector on the global… Read More
Scientists have uncovered a previously unknown mechanism that helps breast cancer cells survive the intense stresses of being malignant, revealing a promising new target for future cancer therapies. A new study has shown that breast cancer cells become highly dependent on a cell membrane protein called GPR89… Read More
Caribou Biosciences has announced that it is discontinuing its two allogeneic CAR-T cell therapy programmes due to financing constraints. It will discontinue development of vispa-cel for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin lymphoma and CB-011 for the treatment of r/r multiple myeloma. … Read More
MimiVax and Roswell Park Comprehensive Cancer Center have announced results from the SURVIVE Phase IIb clinical trial evaluating novel cancer vaccine, SurVaxM, in patients with newly diagnosed glioblastoma. The data reflect the first reportable results from the fully enrolled clinical trial, which has been underway since 2022… Read More
Cancer Research UK has signed an agreement with ORIC Pharmaceuticals to advance ORIC-259, a potential first-in-class CIP2A-targeted therapy, into clinical development. Under the agreement, Cancer Research UK’s Centre for Drug Development (CDD) will fully fund, sponsor, design and execute a Phase I/II clinical trial of ORIC-259, including… Read More
Roswell Park Comprehensive Cancer Center and Generate Biomedicines have dosed the first patient in a first-in-human clinical trial evaluating GB-5267, an autologous IL‑18–armoured CAR T-cell therapy. The therapy is designed to overcome key barriers that have limited the success of cellular therapies in solid tumours. … Read More